Redeye provides a research update following the Q2 report published by Initiator Pharma earlier toda...
Redeye regards BrightBid’s Q2 as a mixed-bag quarter, where the substantial cost cuts are the positi...
CoinShares International (CS) posted a strong adjusted EBITDA in Q224 of £26.
Loihde reports its H1 results on August 27th. We expect slight net sales growth and a clear y/y prof...
Redeye sees a solid report with Q2 numbers mainly in-line with our expectations.
Redeye returns with an updated view of Egetis Therapeutics following the Q2 report and recent events...
Redeye comments on Heliospectra’s Q2 results, noting that sales were weaker than expected due to sho...
Tumorad-01 is progressing towards the DMC meeting and the study is about to expand the number of pat...
Redeye states the report was in line with preannounced figures and slightly ahead on sales with a 25...
CirChem (”CirChem” eller ”Bolaget”) har nyligen stängt böckerna för Q2-24, ett kvartal präglat av fo...
Redeye provides a research update following the Q2 report recently published by Coegin Pharma.
Sales 20% and EBIT adj. 34% vs. ABGSCe Strong quarter with record turnover Set to enter next phase o...
Redeye provides an update following WntResearch’s Q2 report.
Gapwaves carried over its momentum from Q1 into the Q2 report, beating Redeye's estimates and consen...
Redeye leaves a research update following Klaria Pharma’s recently published Q2 2024 report.
First Venture publicerade den 22 augusti 2024 bolagets delårsrapport för det andra kvartalet av 2024...
We lower '24e revenue by 21%, but lift '26e by 18% 2nd IPU design win secured, pipeline continues to...
Redeye updates on Northbaze following its Q2 results, which were stronger than expected in both sale...
Redeye comments on Active Biotech's Q2 report. New results with naptumomab + docetaxel were presente...
Redeye updates its estimates following Surgical Science’s Q2 2024 report, which featured a sequentia...
